2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia [5]

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 170-173

  Warzocha, K ^a   Fabianowska Majewska, K ^a   Blonski J ^a   Krykowski, E ^a   Robak, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOSYLHOMOCYSTEINASE; CLADRIBINE;

ADULT; AGED; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME INHIBITION; HUMAN; LETTER; PRIORITY JOURNAL;

ADENOSINE DEAMINASE; ADENOSYLHOMOCYSTEINASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLADRIBINE; HUMANS; HYDROLASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED;

EID: 0031020978     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00347-4     Document Type: Letter

References (15)

1. 1. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991, 49, 239-268.
2. 2. Spasokoukotskaja T, Arnér ESJ, Brosjö O, et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 1995, 31A, 202-208.
3. 3. Petzer AL, Bilgeri R, Zilian U, et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 1992, 78, 2583-2587.
4. 4. Robak T, Korycka A. The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon α (IFNα) or interferon γ (IFN γ) on granulocyte-macrophage progenitor cell (CFU-GM) and clonogenic blasts (CFU-L) in in vitro cultures. Leuk Lymph 1996, 21, 161-168.
5. 5. Fabianowska-Majewska K, Wasiak TJ, Warzocha K, et al. A new mechanism of toxicity of 2-chlorodeoxyadenosine (2-CdA). Adv Exp Med Biol 1995, 370, 125-128.
6. 6. Fabianowska-Majewska K, Tybor K, Duley J, Simmonds A. The influence of 2-chloro-2′-deoxyadenosine on metabolism of deoxyadenosine in human primary CNS lymphoma. Biochem Pharmacol 1995, 9, 1379-1383.
7. 7. Cheson BD, Bennet JM, Rai KR. Guidelines for clinical protocols for chronic lymphocytic leukemia. Recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 1988, 29, 152-163.
8. 8. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci 1977, 74, 5677-5681.
9. 9. Kredich NM, Martin DW. 5-Adenosylhomocysteine hydrolase in adenosine mediated toxicity in mouse T lymphoma cells. Cell 1977, 12, 931-935.
10. 10. Abeles RH, Tashjian AH, Fish S. The mechanism of inactivation of S-adenosylhomocysteine by 2′-deoxyadenosine. Biochem Biophys Res Commun 1980, 95, 612-617.
11. 11. Chiang PK. S-adenosylhomocysteine hydrolase as a pharmacological target for the inhibition of transmethylation. Adv Exp Med Biol 1984, 165B, 199-205.
12. 12. Metz J. Cobalamin deficiency and the pathogenesis of nervous system disease. Ann Rev Nutr 1992, 12, 59-79.
13. 13. Warzocha K, Krykowski E, Gòra-Tybor J, Fronczak A, Robak T. Fulminant 2-chlorodeoxyadenosine - related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma. Leuk Lymph 1996, 21, 343-346.
14. 14. Wolos JA, Frondorf KA, Davis GF, Jarvi ET, McCarthy JR, Bowlin TL. Selective inhibition of T-cell activation by an inhibitor of S-adenosyl-L-homocysteine hydrolase. J Immunol 1993, 150, 3264-3273.
15. 15. Paller AS, Arnsmeier SL, Clark SH, Mirkin B. Z-4′,5′-didehydro-5′-deoxy-5′-fluoroadenosine (MDL 28,842), an irreversible inhibitor of S-adenosylhomocysteine hydrolase, suppresses proliferation of cultured keratinocytes and squamous carcinoma cell lines. Cancer Res 1993, 53, 6058-6060.